Essential to our hypothesis, the degree of hematoma resolution (measured by quantitating Hb and iron remaining in the brain at day 7) was significantly improved with ITE treatment in the AhRloxP control mice, but not in MG-AhR-KO mice (Figure 6(c)). This evidence concerns the gene AHR and myasthenia gravis.